Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study

被引:84
作者
Louvet, Alexandre [1 ]
Labreuche, Julien [2 ]
Moreno, Christophe [3 ]
Vanlemmens, Claire [5 ]
Moirand, Romain [6 ]
Feray, Cyrille [7 ]
Dumortier, Jerome [8 ]
Pageaux, Georges-Philippe [11 ]
Bureau, Christophe [12 ]
Chermak, Faiza [13 ]
Duvoux, Christophe [14 ]
Thabut, Dominique [15 ]
Leroy, Vincent [16 ]
Carbonell, Nicolas [17 ]
Rolland, Benjamin [9 ,10 ]
Salame, Ephrem [18 ]
Anty, Rodolphe [19 ]
Gournay, Jerome [20 ]
Delwaide, Jean [21 ]
Silvain, Christine [22 ]
Lucidi, Valerio [4 ]
Lassailly, Guillaume [1 ]
Dharancy, Sebastien [1 ]
Nguyen-Khac, Eric [23 ]
Samuel, Didier [7 ]
Duhamel, Alain [2 ]
Mathurin, Philippe [1 ]
机构
[1] CHU Lille, Serv Malad Appareil Digestif, F-59037 Lille, France
[2] CHU Lille, Dept Biostat, Lille, France
[3] Univ Libre Bruxelles, Erasme Hosp, Dept Gastroenterol Hepatopancreatol & Digest Onco, Brussels, Belgium
[4] Univ Libre Bruxelles, Erasme Hosp, Liver Transplant Unit, Dept Abdominal Surg, Brussels, Belgium
[5] CHU Besancon, Serv Hepatol, Hop Jean Minjoz, Besancon, France
[6] Univ Rennes, INRAE, INSERM, Unite Nutr Metab & Canc,CHU Rennes,Serv Malad Foi, Rennes, France
[7] Univ Paris Saclay, Hop Paul Brousse, AP HP, INSERM,Res Unit 1193,Ctr Hepatobiliaire, Paris, France
[8] Hop Edouard Herriot, Federat Specialites Digest, Lyon, France
[9] Hosp Civils Lyon, Serv Univ Addictol Lyon, Ctr Hosp Le Vinatier, Lyon, France
[10] Univ Lyon, Lyon, France
[11] CHU Montpellier, Dept Hepatogastroenterol & Transplantat Hepat, Montpellier, France
[12] CHU Toulouse, Serv Hepatol, Hop Rangueil, Toulouse, France
[13] CHU Bordeaux, Serv Hepatogastroenterol, Hop Haut Leveque, Bordeaux, France
[14] Hop Henri Mondor, AP HP, Serv Hepatol, Paris, France
[15] Sorbonne Univ, Serv Hepatogastroenterol, Hop Pitie Salpetriere, AP HP, Paris, France
[16] CHU Grenoble, Clin Hepatogastroenterol, Grenoble, France
[17] Hop St Antoine, Serv Hepatol, AP HP, Paris, France
[18] CHU Tours, Serv Chirurg Hipat & Transplantat, Tours, France
[19] Univ Cote dAzur, Ctr Hosp Univ, INSERM, U1065,C3M, Nice, France
[20] CHU Nantes, Serv Hepatogastroenterol, Nantes, France
[21] CHU Liege, Serv Hepatogastroenterol, Liege, Belgium
[22] CHU Poitiers, Serv Hepatogastroenterol, Poitiers, France
[23] CHU Amiens, Serv Hepatogastroenterol, Amiens, France
来源
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2022年 / 7卷 / 05期
关键词
SELF-REPORTS; DRINKING; DISEASE; RELIABILITY; EFFICACY;
D O I
10.1016/S2468-1253(21)00430-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Early liver transplantation for severe alcohol-related hepatitis is an emerging treatment option. We aimed to assess the risk of alcohol relapse 2 years after early liver transplantation for alcohol-related hepatitis compared with liver transplantation for alcohol-related cirrhosis after at least 6 months of abstinence. Methods We conducted a multicentre, non-randomised, non-inferiority, controlled study in 19 French and Belgian hospitals. All participants were aged 18 years or older. There were three groups of patients recruited prospectively: patients with severe alcohol-related hepatitis who did not respond to medical treatment and were eligible for early liver transplantation according to a new selection scoring system based on social and addiction items that can be quantified in points (early transplantation group); patients with alcohol-related cirrhosis listed for liver transplantation after at least 6 months of abstinence (standard transplantation group); patients with severe alcohol-related hepatitis not responding to medical treatment not eligible for early liver transplantation according to the selection score (not eligible for early transplantation group), this group did not enter any further liver transplantation processes. We also defined a historical control group of patients with severe alcohol-related hepatitis unresponsive to medical therapy and non-transplanted. The primary outcome was the non-inferiority of 2-year rate of alcohol relapse after transplantation in the early transplantation group compared with the standard transplantation group using the alcohol timeline follow back (TLFB) method and a prespecified non-inferiority margin of 10%. Secondary outcomes were the pattern of alcohol relapse, 2-year survival rate post-transplant in the early transplantation group compared with the standard transplantation group, and 2-year overall survival in the early transplantation group compared with patients in the not eligible for early transplantation group and historical controls. This trial is registered with ClinicalTrials.gov, NCT01756794. Findings Between Dec 5, 2012, and June 30, 2016, we included 149 patients with severe alcohol-related hepatitis: 102 in the early transplantation group and 47 in the not eligible for early transplantation group. 129 patients were included in the standard transplantation group. 68 patients in the early transplantation group and 93 patients in the standard transplantation group received a liver transplant. 23 (34%) patients relapsed in the early transplantation group, and 23 (25%) patients relapsed in the standard transplantation group; therefore, the non-inferiority of early transplantation versus standard transplantation was not demonstrated (absolute difference 9.1% [95% CI -infinity to 21.1]; p=0.45). The 2-year rate of high alcohol intake was greater in the early transplantation group than the standard transplantation group (absolute difference 16.7% [95% CI 5.8-27.6]) The time spent drinking alcohol was not different between the two groups (standardised difference 0.24 [95% CI -0.07 to 0.55]), but the time spent drinking a large quantity of alcohol was higher in the early transplantation group than the standard transplantation group (standardised difference 0.50 [95% CI 0.17-0.82]). 2-year post-transplant survival was similar between the early transplantation group and the standard transplantation group (hazard ratio [HR] 0.87 [95% CI 0.33-2.26]); 2-year overall survival was higher in the early transplantation group than the not eligible for early transplantation group and historical controls (HR 0.27 [95% CI 0.16-0.47] and 0.21 [0.13-0.32]). Interpretation We cannot conclude non-inferiority in terms of rate of alcohol relapse post-transplant between early liver transplantation and standard transplantation. High alcohol intake is more frequent after early liver transplantation. This prospective controlled study confirms the important survival benefit related to early liver transplantation for severe alcohol-related hepatitis; and this study provides objective data on survival and alcohol relapse to tailor the management of patients with severe alcohol-related hepatitis. Copyright (C) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码:416 / 425
页数:10
相关论文
共 28 条
  • [1] Combined pharmacotherapies and behavioral interventions for alcohol dependence - The COMBINE study: A randomized controlled trial
    Anton, RF
    O'Malley, SS
    Ciraulo, DA
    Cisler, RA
    Couper, D
    Donovan, DM
    Gastfriend, DR
    Hosking, JD
    Johnson, BA
    LoCastro, JS
    Longabaugh, R
    Mason, BJ
    Mattson, ME
    Miller, WR
    Pettinati, HM
    Randall, CL
    Swift, R
    Weiss, RD
    Williams, LD
    Zweben, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (17): : 2003 - 2017
  • [2] Impact of a first study of early transplantation in acute alcoholic hepatitis: Results of a nationwide survey in french liver transplantation programs
    Antonini, Teresa Maria
    Guillaud, Olivier
    Dumortier, Jerome
    Dharancy, Sebastien
    Saliba, Faouzi
    Mathurin, Philippe
    Duclos-Vallee, Jean-Charles
    Duvoux, Christophe
    [J]. LIVER TRANSPLANTATION, 2018, 24 (06) : 841 - 844
  • [3] Survey of Liver Transplantation Practices for Severe Acute Alcoholic Hepatitis
    Bangaru, Saroja
    Pedersen, Mark R.
    MacConmara, Malcolm P.
    Singal, Amit G.
    Mufti, Arjmand R.
    [J]. LIVER TRANSPLANTATION, 2018, 24 (10) : 1357 - 1362
  • [4] Consensus Conference:: Indications for liver transplantation, January 19 and 20, 2005, Lyon-Palais des Congres -: Text of recommendations (long version)
    Boudjema, K
    Samuel, D
    Balabaud, C
    Belghiti, J
    Bismuth, H
    Calmus, Y
    Chazouillères, O
    Cherqui, D
    Chiche, L
    Cohen, S
    Dosquet, P
    Duvoux, C
    Jacquelinet, C
    Launois, B
    LeToublon, C
    Messner, M
    Pageaux, GP
    Paindavoine, C
    Partensky, C
    Sicard, D
    Benyamina, A
    Duplan, AB
    Bronowicki, JP
    Danet, C
    Gendrel, D
    Hourmant, M
    Lazorthes, F
    le Loup, G
    Nancy, JL
    Pariente, EA
    Petitnicolas, C
    Rousset, H
    Tirel, PBB
    Torpier, G
    Adam, R
    Azoulay, D
    Berenguer, M
    Bismuth, H
    Boillot, O
    Boudjema, K
    Calmus, Y
    Camby, C
    Chiche, L
    Clavien, PA
    Duclos-Vallee, JC
    Durand, F
    Duvoux, C
    Emond, J
    Hadengue, A
    le Treut, YP
    [J]. LIVER TRANSPLANTATION, 2006, 12 (06) : 998 - 1011
  • [5] Liver transplantation for alcoholic liver disease among Canadian transplant centres: A national study
    Chandok, Natasha
    Aljawad, Mohammed
    White, Angela
    Hernandez-Alejandro, Roberto
    Marotta, Paul
    Yoshida, Eric M.
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY, 2013, 27 (11): : 643 - 646
  • [6] Applying clinical significance methodology to alcoholism treatment trials: Determining recovery outcome status with individual- and population-based measures
    Cisler, RA
    Kowalchuk, RK
    Saunders, SM
    Zweben, A
    Trinh, HQ
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2005, 29 (11) : 1991 - 2000
  • [7] The validity of self-reports of alcohol consumption: state of the science and challenges for research
    Del Boca, FK
    Darkes, J
    [J]. ADDICTION, 2003, 98 : 1 - 12
  • [8] Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy
    Donckier, Vincent
    Lucidi, Valerio
    Gustot, Thierry
    Moreno, Christophe
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (04) : 866 - 871
  • [9] Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for Alcohol Clinical Trials
    Falk, Daniel
    Wang, Xin Qun
    Liu, Lei
    Fertig, Joanne
    Mattson, Margaret
    Ryan, Megan
    Johnson, Bankole
    Stout, Robert
    Litten, Raye Z.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 34 (12) : 2022 - 2034
  • [10] Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials A Secondary Analysis of 3 Randomized Clinical Trials
    Falk, Daniel E.
    O'Malley, Stephanie S.
    Witkiewitz, Katie
    Anton, Raymond F.
    Litten, Raye Z.
    Slater, Megan
    Kranzler, Henry R.
    Mann, Karl F.
    Hasin, Deborah S.
    Johnson, Bankole
    Meulien, Didier
    Ryan, Megan
    Fertig, Joanne
    Isenberg, Keith
    McCann, David
    Meyer, Roger E.
    O'Brien, Charles
    Silverman, Bernard
    Trinquet, Francoise
    Zakine, Benjamin
    Aubin, Henri-Jean
    Ramey, Tanya
    [J]. JAMA PSYCHIATRY, 2019, 76 (04) : 374 - 381